AngioDynamics, Inc. (ANGO)
| Market Cap | 486.99M +3.6% |
| Revenue (ttm) | 325.38M +8.2% |
| Net Income | -32.94M |
| EPS | -0.79 |
| Shares Out | 42.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,136,940 |
| Open | 11.05 |
| Previous Close | 11.05 |
| Day's Range | 11.05 - 11.63 |
| 52-Week Range | 9.39 - 16.29 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 19.75 (+70.55%) |
| Earnings Date | Oct 8, 2026 |
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration dev... [Read more]
Financial Performance
In fiscal year 2026, AngioDynamics's revenue was $320.17 million, an increase of 9.46% compared to the previous year's $292.50 million. Losses were -$36.74 million, 8.09% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $19.75, which is an increase of 70.55% from the latest price.
News
AngioDynamics announces Humana Medicare Advantage policy for NanoKnife
AngioDynamics (ANGO) announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination L40205 medical necessity criteria for irreversible electroporation, ...
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics price target lowered to $18 from $19 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on AngioDynamics (ANGO) to $18 from $19 and keeps a Buy rating on the shares. The company reported inline fiscal…
AngioDynamics Earnings Call Transcript: Q1 2027
Q1 revenue grew 6.9%, led by 13.2% Med Tech growth, with improved adjusted loss and EBITDA. FY27 guidance was maintained; growth catalysts include Auryon, AlphaVac, NanoKnife reimbursement and clinical programs.
AngioDynamics Earnings release: Q1 2027
AngioDynamics released its Q1 2027 earnings on October 8, 2026, summarizing the period's financial results.
AngioDynamics Slides: Q1 2027
AngioDynamics has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on October 8, 2026.
AngioDynamics Quarterly report: Q1 2027
AngioDynamics has published its Q1 2027 quarterly earnings report on October 8, 2026.
AngioDynamics Proxy statement: Proxy filing
AngioDynamics filed a proxy statement on October 8, 2026, providing details for shareholder voting and corporate governance matters.
AngioDynamics Proxy statement: Proxy filing
AngioDynamics filed a proxy statement on October 8, 2026, providing details for shareholder voting and corporate governance matters.
AngioDynamics sees FY27 tariff impact ‘broadly similar’ to FY26
For fiscal 2027, the company expects a tariff impact broadly similar to fiscal 2026, (excluding any tariff refunds) based on its current view of the tariff situation, which remains dynamic…
AngioDynamics sees FY27 adjusted EBITDA $13M-$16M
Sees FY27: Med Tech Net Sales Growth 12%-15%; Med Device Net Sales Growth Flat; Gross margin 54%-55%.
AngioDynamics names Eric Honroth as CEO, succeeding Jim Clemmer
AngioDynamics (ANGO) announced the appointment of Eric Honroth as President and CEO and a member of the Board of Directors, effective November 2. Honroth will succeed Jim Clemmer, who will…
AngioDynamics reports Q1 adjusted EPS (4c), consensus (11c)
Reports Q1 revenue $80.9M, consensus $80.5M. “Our first quarter results reflect the continued, consistent execution we’ve built into this business,” said Jim Clemmer, President and Chief Executive Off...
AngioDynamics sees FY27 adjusted EPS (29c)-(24c), consensus (27c)
Sees FY27 revenue $336M-$341M, consensus $337.32M.
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
3 Small-Cap Stocks Analysts Expect to Rally over 35%
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Progress Software ($PRGS), and AngioDynamics ($ANGO) as companies...
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: Canaccord Genuity's 46th Annual Growth Conference
MedTech now drives nearly half of revenue, with sustained double-digit growth expected to continue as the business shifts away from legacy devices. Auryon, mechanical thrombectomy, and NanoKnife platforms are expanding into new markets, supported by clinical trials and reimbursement wins. Margin expansion, positive cash flow, and a CEO transition are key themes for FY 2027.
AngioDynamics Slides: Canaccord Genuity's 46th Annual Growth Conference
AngioDynamics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
3 Small-Cap Stocks Analysts Expect to Rally Big
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
AngioDynamics to Participate in Upcoming Investor Conferences
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and 40%+ Upside, According to Analysts
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
AngioDynamics price target raised to $19 from $16 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on AngioDynamics (ANGO) to $19 from $16 and keeps a Buy rating on the shares. The company reported a sales…